Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Rastogi, P; O'Shaughnessy, J; Martin, M; Boyle, F; Cortes, J; Rugo, HS; Goetz, MP; Hamilton, EP; Huang, CS; Senkus, E; Tryakin, A; Cicin, I; Testa, L; Neven, P; Huober, J; Shao, ZM; Wei, R; André, V; Munoz, M; San Antonio, B; Shahir, A; Harbeck, N; Johnston, S.

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(9): Nº de citas: 174 [doi:10.1200/JCO.23.01994]

Slamon, DJ; Diéras, V; Rugo, HS; Harbeck, N; Im, SA; Gelmon, KA; Lipatov, ON; Walshe, JM; Martin, M; Chavez-MacGregor, M; Bananis, E; Gauthier, E; Lu, DR; Kim, S; Finn, RS.

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(9): Nº de citas: 140 [doi:10.1200/JCO.23.00137]

Villacampa, G; Pascual, T; Braso-Maristany, F; Pare, L; Martinez-Saez, O; Cortes, J; Ciruelos, E; Martin, M; Conte, P; Carey, LA; Fernandez, A; Harbeck, N; Marin-Aguilera, M; Vivancos, A; Curigliano, G; Villagrasa, P; Parker, JS; Perou, CM; Prat, A; Tolaney, SM.

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network d Breast dataset (SCAN-B)

Esmo Open. 2024; 9(3): Nº de citas: 17 [doi:10.1016/j.esmoop.2024.102388]

Tolaney, SM; Guarneri, V; Seo, JH; Cruz, J; Abreu, MH; Takahashi, M; Barrios, C; McIntyre, K; Wei, R; Munoz, M; San Antonio, B; Liepa, AM; Martin, M; Johnston, SRD; Kellokumpu-Lehtinen, PL; Harbeck, N.

Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

EUROPEAN JOURNAL OF CANCER. 2024; 199: Nº de citas: 24 [doi:10.1016/j.ejca.2024.113555]

Juric, D; Barve, M; Vaishampayan, U; Roda, D; Calvo, A; Janez, NM; Trigo, J; Greystoke, A; Harvey, RD; Olszanski, AJ; Opyrchal, M; Spira, A; Thistlethwaite, F; Jiménez, B; Sappal, JH; Kannan, K; Riley, J; Li, CRY; Li, C; Gregory, RC; Miao, HRY; Wang, SN.

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

Cancer Medicine. 2024; 13(5): [doi:10.1002/cam4.6776]

García-Alfonso, P; Vera, R; Aranda, E; Elez, E; Rivera, F.

Delphi consensus for the third-line treatment of metastatic colorectal cancer

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(6): 1429-1437 Nº de citas: 1 [doi:10.1007/s12094-023-03369-1]

Fernandez-Martinez, NF; Rodriguez-Barranco, M; Huerta, JM; Gil, F; Olmedo, P; Molina-Montes, E; Guevara, M; Zamora-Ros, R; Jimenez-Zabala, A; Colorado-Yohar, SM; Ardanaz, E; Bonet, C; Amiano, P; Chirlaque, MD; Perez-Gomez, B; Jimenez-Moleon, JJ; Martin-Jimenez, M; de Santiago, E; Sanchez, MJ.

Breast cancer risk for the joint exposure to metals and metalloids in women: Results from the EPIC-Spain cohort

SCIENCE OF THE TOTAL ENVIRONMENT. 2024; 912: 168816-168816 Nº de citas: 11 [doi:10.1016/j.scitotenv.2023.168816]

Galsky, MD; Guan, XN; Rishipathak, D; Rapaport, AS; Shehata, HM; Banchereau, R; Yuen, K; Varfolomeev, E; Hu, RZ; Han, CJ; Li, HC; Liang, YX; Vucic, D; Wang, L; Zhu, J; Yu, HC; Herbst, RH; Hajaj, E; Kiner, E; Bamias, A; De Santis, M; Davis, ID; Arranz, JA; Kikuchi, E; Bernhard, S; Williams, P; Lee, C; Mellman, I; Sanjabi, S; Johnston, R; Black, PC; Grande, E; Mariathasan, S.

Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer

CELL REPORTS MEDICINE. 2024; 5(2): Nº de citas: 47 [doi:10.1016/j.xcrm.2024.101393]

Pacheco-Barcia, V; Custodio-Cabello, S; Carrasco-Valero, F; Palka-Kotlowska, M; Mariño-Mendez, A; Carmona-Bayonas, A; Gallego, J; Martín, AJM; Jimenez-Fonseca, P; Cabezon-Gutierrez, L.

Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial

World Journal of Gastrointestinal Oncology. 2024; 16(2): Nº de citas: 6 [doi:10.4251/wjgo.v16.i2.386]

Martín, AM; Trujillo-Santos, AJ; Martí, E; Jara-Palomares, L; Montero, RM; Gallardo, E; López-Núñez, JJ; Brozos-Vázquez, E; Robles-Marinas, V; Pérez-Segura, P; Ruíz-Artacho, P.

Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients' healthcare in Spain

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(6): 1319-1328 [doi:10.1007/s12094-023-03379-z]

Ciruelos, E; García-Sáenz, JA; Gavilá, J; Martín, M; Rodríguez, CA; Rodríguez-Lescure, A.

Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(7): 1539-1548 Nº de citas: 21 [doi:10.1007/s12094-024-03383-x]

Morales, MG; Visa, L; Vázquez, EB; Batlle, JF; Shahi, PK; Sáez, BL; Hernández, BLD; Macarulla, T; Sarrió, RG.

Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(7): 1570-1583 Nº de citas: 6 [doi:10.1007/s12094-024-03386-8]

Loibl S; André F; Bachelot T; Barrios CH; Bergh J; Burstein HJ; Cardoso MJ; Carey LA; Dawood S; Del Mastro L; Denkert C; Fallenberg EM; Francis PA; Gamal-Eldin H; Gelmon K; Geyer CE; Gnant M; Guarneri V; Gupta S; Kim SB; Krug D; Martin M; Meattini I; Morrow M; Janni W; Paluch-Shimon S; Partridge A; Poortmans P; Pusztai L; Regan MM; Sparano J; Spanic T; Swain S; Tjulandin S; Toi M; Trapani D; Tutt A; Xu B; Curigliano G; Harbeck N.

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

ANNALS OF ONCOLOGY. 2024; 35(2): 159-182 Nº de citas: 626 [doi:10.1016/j.annonc.2023.11.016]

Barrio-Alonso, C; Nieto-Valle, A; Garcia-Martinez, E; Gutiérrez-Seijo, A; Parra-Blanco, V; Márquez-Rodas, I; Avilés-Izquierdo, JA; Sánchez-Mateos, P; Samaniego, R.

Chemokine profiling of melanoma-macrophage crosstalk identifies CCL8 and CCL15 as prognostic factors in cutaneous melanoma

JOURNAL OF PATHOLOGY. 2024; 262(4): 495-504 Nº de citas: 10 [doi:10.1002/path.6252]

Cohen, AT; Creeper, KJ; Alikhan, R; Er, C; Connors, JM; Huisman, MV; Munoz, A; Vescovo, G; Bauersachs, R; Ageno, W; Agnelli, G; Becattini, C.

Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer

THROMBOSIS AND HAEMOSTASIS. 2024; 124(07): 676-683 Nº de citas: 5 [doi:10.1055/s-0043-1778642]

González, MM; Sanz-Pastor, AG; Gómez, RA; Torrecilla, NB; Moreno, DM; Fernández, LG; Rivas, AM; Guerra, AL; Alvarez, R; Arranz, JA; Rodas, IM; Escudero, V; Sanjurjo, M; Vallejo, JM; Martín, M; Albarrán, OG.

Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction

Endocrine Metabolic & Immune Disorders-Drug Targets. 2024; 24(14): 1628-1639 Nº de citas: 1 [doi:10.2174/0118715303280679240206100137]

García-Sáenz, JA; Marmé, F; Untch, M; Bonnefoi, H; Kim, SB; Bear, H; Mc Carthy, N; Gelmon, K; Martin, M; Kelly, CM; Reimer, T; Toi, M; Law, E; Bhattacharyya, H; Gnant, M; Makris, A; Seiler, S; Burchardi, N; Nekljudova, V; Loibl, S; Rugo, HS.

Patient-reported outcomes in high-risk HR+ /HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

EUROPEAN JOURNAL OF CANCER. 2024; 196: 113420-113420 Nº de citas: 3 [doi:10.1016/j.ejca.2023.113420]

Bamias, A; Davis, I; Galsky, M; Arranz, JA; Kikuchi, E; Grande, E; Muro, XGD; Park, SH; De Giorgi, U; Alekseev, B; Mencinger, M; Izumi, K; Schutz, FA; Puente, J; Li, JR; Panni, S; Gumus, M; Oezgueroglu, M; Mariathasan, S; Poloz, Y; Bene-Tchaleu, F; Lee, C; Bernhard, S; De Santis, M.

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

LANCET ONCOLOGY. 2024; 25(1): 46-61 Nº de citas: 36 [doi:10.1016/S1470-2045(23)00539-9]